Potential Ameliorating Role of Spironolactone in Trastuzumab-induced Cardiotoxicity: A Narrative Review
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 12 No. 2 (2022),
23 May 2022
,
Page 36127
https://doi.org/10.32598/ijmtfm.vi.36127
Abstract
Background: Around 20% of breast cancers (BCs) overexpress Human Epidermal Growth Factor Receptor 2 (HER-2). HER-2 overexpression is associated with increased tumor aggressiveness and poor prognosis. Trastuzumab (an anti-HER2 monoclonal antibody) has been reported to improve overall survival in early-stage and metastatic BCs, but at the expense of increasing cardiac morbidity. In the current review study, we aims to discuss the pathogenesis of trastuzumab-induced cardiotoxicity and the potential ameliorating role of spironolactone in this regard.
Methods: The search strategy aimed to identify both published and unpublished studies. First off, we identified keywords and index terms, including trastuzumab, cardiotoxicity, heart failure, and spironolactone to conduct a broad search in PubMed, Embase, Scopus, and Web of Science, using the aforementioned keywords either individually or in combination. Lastly, the reference list of all identified articles was also evaluated. Our study included observational and interventional studies, case-reports, and systematic reviews and meta-analyses.
Results: Trastuzumab could deteriorate mitochondrial function and subsequently leads to the accumulation of Reactive Oxygen Species (ROS) in cardiomyocytes. Published clinical studies offered conflicting results regarding the efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in respect of trastuzumab-induced cardiotoxicity. On the other hand, spironolactone was found to have both antioxidant and anti-inflammatory properties. Recent in-vivo studies supported the cardioprotective effect of spironolactone through maintaining mitochondrial ultrastructure and reducing ROS production.
Conclusion: Although spironolactone mitigates oxidative stress and mitochondrial dysfunction, there is a lack of clinical evidence to support the effectiveness of spironolactone in trastuzumab-induced cardiotoxicity. Design and implementation of clinical trials are recommended to determine the potential beneficial effects of spironolactone on trastuzumab-induced cardiotoxicity.
- Spironolactone
- Trastuzumab
- cardiotoxicity
- Heart failure
- Cardio-oncology
- Chemotherapy
- Mitochondria
- Oxidative stress
How to Cite
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021; 71(3):209-49. [DOI:10.3322/caac.21660] [PMID]
Moo T-A, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clinics. 2018; 13(3):339-54. [DOI:10.1016/j.cpet.2018.02.006] [PMID] [PMCID]
Nowsheen S, Viscuse PV, O’Sullivan CC, Sandhu NP, Haddad TC, Blaes A, et al. Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer. Curr Breast Cancer Rep. 2017; 9(3):173-82. [DOI:10.1007/s12609-017-0249-4] [PMID] [PMCID]
Nemeth BT, Varga ZV, Wu WJ, Pacher P. Trastuzumab cardiotoxicity: From clinical trials to experimental studies. Br J Pharmacol. 2017; 174(21):3727-48. [DOI:10.1111/bph.13643] [PMID] [PMCID]
Zohrian F, Alizadehasl A, Zahedi L, Ghaderian H, Anbiaee R, Azade P. Assessment of cardiac function by advanced echocardiography in breast cancer patients (HER2 Positive vs HER2 Negative). Multidiscip Cardiovasc Ann. 2020; 11(2):e103004. [DOI:10.5812/mca.103004]
Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: Review of results from 37,992 patients. Cancer Metastasis Rev. 2015; 34(1):157-64. [DOI:10.1007/s10555-015-9552-6] [PMID] [PMCID]
Azin A, Zohreh R. Relationship between Breast Cancer and Cardiac Myxoma. Int J Hematol Oncol Stem Cell Res. 2021; 15(2):75-6. [DOI:10.18502/ijhoscr.v15i2.6037]
Alizadehasl A, Maleki M, Noohi F, Adimi S, Emami A, Mousavi A, et al. The cardiac effects of radiotherapy on women with breast cancer based on laterality. Int Cardiovas Res J. 2021; 15(1):8-15. https://brieflands.com/articles/ircrj-112489.pdf
Franchi M, Tritto R, Torroni L, Reno C, La Vecchia C, Corrao G. Effectiveness and healthcare cost of adding trastuzumab to standard chemotherapy for first-line treatment of metastatic gastric cancer: A population-based cohort study. Cancers. 2020; 12(6):1691. [DOI:10.3390/cancers12061691] [PMID] [PMCID]
Dokmanovic M, King KE, Mohan N, Endo Y, Wu WJ. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab. Expert Opin Drug Metab Toxicol. 2017; 13(7):755-66. [DOI:10.1080/17425255.2017.1337746] [PMID]
Lin D, Khan U, Goetze TO, Reizine N, Goodman KA, Shah MA, et al. Gastroesophageal junction adenocarcinoma: Is there an optimal management? Am Soc Clin Oncol Educ Book. 2019; 39:e88-95. [DOI:10.1200/EDBK_236827] [PMID]
Nicolazzi MA, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R, et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018; 22(7):2175-85. [DOI:10.26355/eurrev_201804_14752]
Tsao L-C, Crosby EJ, Trotter TN, Agarwal P, Hwang B-J, Acharya C, et al. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight. 2019; 4(24):e131882. [DOI:10.1172/jci.insight.131882] [PMID] [PMCID]
Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015; 6:368. [DOI:10.3389/fimmu.2015.00368] [PMID] [PMCID]
Gajria D, Chandarlapaty S. HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011; 11(2):263-75. [DOI:10.1586/era.10.226] [PMID] [PMCID]
Barish R, Gates E, Barac A. Trastuzumab-induced cardiomyopathy. Cardiol Clin. 2019; 37(4):407-18. [DOI:10.1016/j.ccl.2019.07.005] [PMID]
Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014; 2014(6):Cd006242. [DOI:10.1002/14651858.CD006242.pub2] [PMID] [PMCID]
Piotrowski G, Gawor R, Stasiak A, Gawor Z, Potemski P, Banach M. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2-a prospective study. Arch Med Sci: AMS. 2012; 8(2):227-35. [DOI:10.5114/aoms.2012.28549] [PMID] [PMCID]
de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, et al. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat. 2020; 179(1):161-71. [DOI:10.1007/s10549-019-05453-z] [PMID] [PMCID]
Alizadehasl A, Amin A, Maleki M, Noohi F, Ghavamzadeh A, Farrashi M. Cardio-oncology discipline: Focus on the necessities in developing countries. ESC Heart Fail. 2020; 7(5):2175-83. [DOI:10.1002/ehf2.12838] [PMID] [PMCID]
De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res. 2010; 106(1):35-46. [DOI:10.1161/CIRCRESAHA.109.205906] [PMID]
Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: A challenge that cardioncology should not miss. Curr Cardiol Rep. 2016; 18(6):51. [DOI:10.1007/s11886-016-0731-z] [PMID]
Alizadehasl A, Maleki M, Noohi F, Peighambari MM, Moradian M. Cardiomyopathies. In: Moradian M, Alizadehasl A, editors. Atlas of echocardiography in pediatrics and congenital heart diseases. Berlin, Heidelberg: Springer; 2021. [DOI:10.1007/978-3-662-62341-1_37]
Herrmann J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020; 17(8):474-502. [DOI:10.1038/s41569-020-0348-1] [PMID] [PMCID]
Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers. Antib Ther. 2018; 1(1):13-7. [DOI:10.1093/abt/tby003] [PMID] [PMCID]
Leemasawat K, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci. 2020; 77(8):1571-89. [DOI:10.1007/s00018-019-03340-w] [PMID]
Brown SA, Ray JC, Herrmann J. Precision cardio-oncology: A systems-based perspective on cardiotoxicity of tyrosine kinase inhibitors and immune checkpoint inhibitors. J Cardiovasc Transl Res. 2020; 13(3):402-16. [DOI:10.1007/s12265-020-09992-5] [PMID] [PMCID]
Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002; 8(5):459-65. [DOI:10.1038/nm0502-459] [PMID]
Bhagat A, Kleinerman ES. Anthracycline-induced cardiotoxicity: Causes, mechanisms, and prevention. Adv Exp Med Biol. 2020; 1257:181-92. [DOI:10.1007/978-3-030-43032-0_15] [PMID]
Tanaka S, Ikari A, Nitta T, Horiuchi T. Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors. Oxf Med Case Reports. 2017; 2017(7):omx038. [DOI:10.1093/omcr/omx038] [PMID] [PMCID]
Bordin P, Volpe C, Adami G, Moretti V, Ermacora P. Irreversible cardiotoxicity after adjuvant treatment with trastuzumab in a case of breast cancer. Tumori J. 2008; 94(5):777-8. [DOI:10.1177/030089160809400527] [PMID]
Gordon LI, Burke MA, Singh ATK, Prachand S, Lieberman ED, Sun L, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. 2009; 284(4):2080-7. [DOI:10.1074/jbc.M804570200] [PMID] [PMCID]
Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E. Chemotherapeutic drugs and mitochondrial dysfunction: Focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev. 2018; 2018:7582730. [DOI:10.1155/2018/7582730] [PMID] [PMCID]
ElZarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS, et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One. 2013; 8(11):e79543. [DOI:10.1371/journal.pone.0079543] [PMID] [PMCID]
Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006; 41(2):228-35. [DOI:10.1016/j.yjmcc.2006.04.007] [PMID] [PMCID]
Rupert CE, Coulombe KL. The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark Insights. 2015; 10(Suppl 1):1-9. [DOI:10.4137/BMI.S20061] [PMID] [PMCID]
Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res. 2009; 315(4):627-37. [DOI:10.1016/j.yexcr.2008.08.015] [PMID] [PMCID]
Li B, Zheng Z, Wei Y, Wang M, Peng J, Kang T, et al. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol. 2011; 10:69. [DOI:10.1186/s12933-018-0707-y] [PMID] [PMCID]
Fock V, Plessl K, Draxler P, Otti GR, Fiala C, Knöfler M, et al. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation. J Cell Sci. 2015; 128(23):4306-16. [DOI:10.1242/jcs.176933] [PMID] [PMCID]
Zoeller JJ, Vagodny A, Taneja K, Tan BY, O’Brien N, Slamon DJ, et al. Neutralization of BCL-2/X(L) enhances the cytotoxicity of T-DM1 in vivo. Mol Cancer Ther. 2019; 18(6):1115-26. [DOI:10.1158/1535-7163.MCT-18-0743] [PMID] [PMCID]
Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. J Card Fail. 2008; 14(5):437-44. [DOI:10.1016/j.cardfail.2008.02.002] [PMID]
An J, Sheikh MS. Toxicology of trastuzumab: An insight into mechanisms of cardiotoxicity. Curr Cancer Drug Targets. 2019; 19(5):400-7. [DOI:10.2174/1568009618666171129222159] [PMID]
Stansfield WE, Ranek M, Pendse A, Schisler JC, Wang S, Pulinilkunnil T, et al. Chapter 4 - The Pathophysiology of Cardiac Hypertrophy and Heart Failure. In: Willis MS, Homeister JW, Stone JR, editors. Cellular and molecular pathobiology of cardiovascular disease. San Diego: Academic Press; 2014. [DOI:10.1016/B978-0-12-405206-2.00004-1]
Laird-Fick HS, Tokala H, Kandola S, Kehdi M, Pelosi A, Wang L, et al. Early morphological changes in cardiac mitochondria after subcutaneous administration of trastuzumab in rabbits: Possible prevention with oral selenium supplementation. Cardiovasc Pathol. 2020; 44:107159. [DOI:10.1016/j.carpath.2019.107159] [PMID]
Kitani T, Ong S-G, Lam CK, Rhee J-W, Zhang JZ, Oikonomopoulos A, et al. Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer. Circulation. 2019; 139(21):2451-65. [DOI:10.1161/CIRCULATIONAHA.118.037357] [PMID] [PMCID]
Almuwaqqat Z, Meisel JL, Barac A, Parashar S. Breast cancer and heart failure. Heart Fail Clin. 2019; 15(1):65-75. [DOI:10.1016/j.hfc.2018.08.007] [PMID]
Caron J, Nohria A. Cardiac toxicity from breast cancer treatment: Can we avoid this? Curr Oncol Rep. 2018; 20(8):61. [DOI:10.1007/s11912-018-0710-1] [PMID]
Ohtani K, Ide T, Hiasa KI, Sakamoto I, Yamashita N, Kubo M, et al. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol. 2019; 108(10):1128-39. [DOI:10.1007/s00392-019-01448-4] [PMID]
Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): A randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clini Oncol. 2017; 35(8):870-7. [DOI:10.1200/JCO.2016.68.7830] [PMID]
Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, et al. Angiotensin ii-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial. JAMA Oncol. 2016; 2(8):1030-7. [DOI:10.1001/jamaoncol.2016.1726] [PMID]
Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen RA. Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or β-blockers in older adults with breast cancer. Am J Clin Oncol. 2018; 41(9):909-18. [DOI:10.1097/COC.0000000000000389] [PMID]
Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019; 73(22):2859-68. [DOI:10.1016/j.jacc.2019.03.495] [PMID] [PMCID]
Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, et al. Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab therapy. Canadian Journal of Cardiology. 2019; 35(2):153-9. [DOI:10.1016/j.cjca.2018.11.028] [PMID]
Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Argüelles O, Amir E, et al. Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: A propensity score‒matched cohort study. J Am Heart Assoc. 2021; 10(2):e018393. [DOI:10.1161/JAHA.119.018393] [PMID] [PMCID]
Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MCO, et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol. 2010; 160(1):77-87. [DOI:10.1111/j.1476-5381.2010.00678.x] [PMID] [PMCID]
Yavas G, Elsurer R, Yavas C, Elsurer C, Ata O. Does spironolactone ameliorate trastuzumab-induced cardiac toxicity? Med Hypotheses. 2013; 81(2):231-4. [DOI:10.1016/j.mehy.2013.04.042] [PMID]
Silva MAB, Bruder-Nascimento T, Cau SBA, Lopes RAM, Mestriner FLAC, Fais RS, et al. Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front Physiol. 2015; 6:269. [DOI:10.3389/fphys.2015.00269]
Lu G, Li J, Zhai Y, Li Q, Xie D, Zhang J, et al. Spironolactone suppresses aldosterone-induced Kv1.5 expression by attenuating mineralocorticoid receptor-Nox1/2/4-mediated ROS generation in neonatal rat atrial myocytes. Biochem Biophys Res Commun. 2019; 520(2):379-84. [DOI:10.1016/j.bbrc.2019.10.039] [PMID]
Sadeghpour A, Alizadehasl A. The right ventricle: A comprehensive review from anatomy, physiology, and mechanics to hemodynamic, functional, and imaging evaluation. Arch Cardiovasc Imaging. 2015; 3(4):e35717. [DOI:10.5812/acvi.35717]
Guitart-Mampel M, Urquiza P, Borges JI, Lymperopoulos A, Solesio ME. Impact of aldosterone on the failing myocardium: Insights from mitochondria and adrenergic receptors signaling and function. Cells. 2021; 10(6):1552. [DOI:10.3390/cells10061552] [PMID] [PMCID]
Shahsavarinia K, Ghojazadeh M, Ghabousian A, Hatefnia F, Soleimanpour M, Soleimanpour H. An Umbrella Review of Clinical Efficacy and Adverse Cardiac Events Associated with Hydroxychloroquine or Chloroquine with or Without Azithromycin in Patients with COVID-19. Anesthesiol Pain Med. 2021; 11(4):e115827. [DOI:10.5812/aapm.115827]
Rozner RN, Freites-Martinez A, Shapiro J, Geer EB, Goldfarb S, Lacouture ME. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat. 2019; 174(1):15-26. [DOI:10.1007/s10549-018-4996-3] [PMID] [PMCID]
Safari S, Khasraghi ZS, Chegeni MA, Ghabousian A, Amini A. The ability of Canadian Syncope risk score in differentiating cardiogenic and non-cardiogenic syncope; A cross-sectional study. Am J Emerg Med. 2021; 50:675-8. [DOI:10.1016/j.ajem.2021.07.034] [PMID]
Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Ann Transl Med. 2018; 6(23):461. [DOI:10.21037/atm.2018.11.16] [PMID] [PMCID]
Verma I, Krishan P, Syngle A. Therapeutic potential of spironolactone in ankylosing spondylitis patients: Relation to disease activity and functional status. Egypt Rheumatol. 2021; 43(2):173-8. [DOI:10.1016/j.ejr.2020.07.005]
Williams TA, Verhovez A, Milan A, Veglio F, Mulatero P. Protective effect of spironolactone on endothelial cell apoptosis. Endocrinology. 2006; 147(5):2496-505. [DOI:10.1210/en.2005-1318] [PMID]
Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension. 2009; 53(2):158-65. [DOI:10.1161/HYPERTENSIONAHA.108.121954] [PMID] [PMCID]
Liu P, Fan J, Wang Z, Zai W, Song P, Li Y, et al. The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells. AMB Express. 2020; 10(1):107. [DOI:10.1186/s13568-020-01044-0] [PMID] [PMCID]
Pecoraro M, Pala B, Di Marcantonio MC, Muraro R, Marzocco S, Pinto A, et al. Doxorubicininduced oxidative and nitrosative stress: Mitochondrial connexin 43 is at the crossroads. Int J Mol Med. 2020; 46(3):1197-209. [DOI:10.3892/ijmm.2020.4669] [PMID] [PMCID]
Martins-Marques T, Ribeiro-Rodrigues T, Batista-Almeida D, Aasen T, Kwak BR, Girao H. Biological functions of connexin43 beyond intercellular communication. Trends Cell Biol. 2019; 29(10):835-47. [DOI:10.1016/j.tcb.2019.07.001] [PMID]
Pecoraro M, Pinto A, Popolo A. Trastuzumab-induced cardiotoxicity and role of mitochondrial connexin43 in the adaptive response. Toxicol In Vitro. 2020; 67:104926. [DOI:10.1016/j.tiv.2020.104926] [PMID]
Qu J, Volpicelli FM, Garcia LI, Sandeep N, Zhang J, Márquez-Rosado L, et al. Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart. Circ Res. 2009; 104(3):365-71. [DOI:10.1161/CIRCRESAHA.108.184044] [PMID] [PMCID]
De Mello WC. Aldosterone disrupts the intercellular flow of glucose in cardiac muscle. Front Endocrinol. 2015; 6:185. [DOI:10.3389/fendo.2015.00185] [PMID] [PMCID]
Mayyas F, Alzoubi KH, Bonyan R. The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes. Cardiovasc Ther. 2017; 35(2). [DOI:10.1111/1755-5922.12242] [PMID]
Chow CK. Vitamin E regulation of mitochondrial superoxide generation. Biol Signals Recept. 2001; 10(1-2):112-24. [DOI:10.1159/000046879] [PMID]
Panth N, Paudel KR, Parajuli K. Reactive oxygen species: A key hallmark of cardiovascular disease. Adv Med. 2016; 2016:9152732-. [DOI:10.1155/2016/9152732] [PMID] [PMCID]
Liu W, Gong W, He M, Liu Y, Yang Y, Wang M, et al. Spironolactone protects against diabetic cardiomyopathy in streptozotocin-induced diabetic rats. J Diabetes Res. 2018; 2018:9232065-. [DOI:10.1155/2018/9232065] [PMID] [PMCID]
Yavas G, Celik E, Yavas C, Elsurer C, Afsar RE. Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy. Rep Pract Oncol Radiother. 2017; 22(4):295-302. [DOI:10.1016/j.rpor.2017.01.004] [PMID] [PMCID]
Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015; 17(1):81-9. [DOI:10.1002/ejhf.196] [PMID]
Alizadehasl A, Ghadimi N, Kaveh S, Maleki M, Ghavamzadeh A, Noohi F, et al. Prevention of anthracycline-induced cardiotoxicity: A systematic review and network meta-analysis. Int J Clin Pharm. 2021; 43(1):25-34. [DOI:10.1007/s11096-020-01146-6] [PMID]
- Abstract Viewed: 534 times
- pdf Downloaded: 184 times